Seer Profit Margin 2021-2022 | SEER
Current and historical gross margin, operating margin and net profit margin for Seer (SEER) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Seer net profit margin as of March 31, 2022 is 0%.
| Seer Annual Profit Margins |
|---|
| Seer Quarterly Profit Margins |
|---|
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.484B | $0.007B |
| Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $161.724B | 9.84 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.093B | 15.93 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $9.948B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.434B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.592B | 6.82 |
| Arcus Biosciences (RCUS) | United States | $1.327B | 33.64 |
| Myovant Sciences (MYOV) | United Kingdom | $0.961B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.483B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.357B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.336B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.154B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.117B | 24.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.092B | 0.00 |
